Related Experiment Video
Updated: Aug 18, 2026
Modeling Brain Metastasis by Internal Carotid Artery Injection of Cancer Cells
Published on: August 2, 2022
[Molecular Targeted Therapies Effective for Brain Metastases and Their Position in Guidelines]
1Division of Neurological Surgery, Chiba Cancer Center.
Abstract:
Various driver gene mutations have been identified, and agents targeting these molecular abnormalities have been developed and are being used in treatment. Some of these driver gene abnormalities are also associated with a high frequency of brain metastases. In patients with non-small cell lung cancer (NSCLC), more than 80% of brain metastases had a molecular target. Tyrosine kinase inhibitors are highly effective against brain metastases in patients with epidermal growth factor receptor-mutated or anaplastic lymphoma kinase fusion-positive NSCLC. Recently, the efficacy of the antibody-drug conjugate, T-DXd, against HER2+ breast cancer has also been confirmed. Many other molecularly targeted therapies are also effective against brain metastases; thus, many patients with brain metastases may benefit from these treatments. Although molecularly targeted therapy has become an important treatment modality for brain metastases, its limitations, such as not being curative and having a limited duration of effect, are also becoming clear. In the era of precision medicine, it is important to coordinate conventional local treatment with individually tailored molecularly targeted therapy. For that purpose, it is essential to understand the efficacy and limitations of targeted therapy for brain metastasis for each molecular target.
Insights
Targeted therapies show promise for brain metastases in non-small cell lung cancer (NSCLC) and HER2+ breast cancer. Understanding the efficacy and limitations of these molecular treatments is crucial for precision medicine approaches.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Driver gene mutations are key in cancer development and treatment.
- Brain metastases are a common complication, particularly in non-small cell lung cancer (NSCLC).
- Over 80% of NSCLC brain metastases harbor molecular targets.
Purpose of the Study:
- To review the efficacy of molecularly targeted therapies against brain metastases.
- To highlight the benefits and limitations of current targeted treatments.
- To emphasize the importance of tailored therapy in precision medicine for brain metastases.
Main Methods:
- Review of existing literature on targeted therapies for brain metastases.
- Analysis of efficacy data for specific molecular targets and agents.
- Discussion of treatment coordination in the context of precision medicine.
Main Results:
- Tyrosine kinase inhibitors are effective for EGFR-mutated or ALK-fusion NSCLC brain metastases.
- Antibody-drug conjugates like T-DXd show efficacy in HER2+ breast cancer brain metastases.
- Various molecularly targeted therapies offer benefits for brain metastases, but limitations exist.
Conclusions:
- Molecularly targeted therapy is a vital treatment modality for brain metastases.
- Current targeted therapies are not curative and have limited duration of effect.
- Integrating conventional local treatments with personalized molecular therapies is essential for optimal patient outcomes.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...